Boston, MA 09/05/2014 (wallstreetpr) – PAREXEL International Corporation (NASDAQ:PRXL), a global leader in biopharmaceutical services, announced its new Senior Vice President for PAREXEL Consulting and Per/Post-Approval Services. The company named Dr. Tracy Tsuetaki for the post today.
Dr. Tsuetaki will be concerned with strategy and operational management for the company’s two businesses. He will also be a part of PAREXEL International Corporation (NASDAQ:PRXL)’s Business Review Committee, as well as its senior-most leadership team. He has also been entitled with the duties of assisting with the implementation and development of the company’s strategic goals.
Experiences And Expertise
Before joining PAREXEL International Corporation (NASDAQ:PRXL), Dr. Tsuetaki was with UnitedHealth Group Inc. (NYSE:UNH). There he was Optum Life Sciences’ Group President and oversaw the Strategic Regulatory and Safety Services organization. He was engaged with pharmacovigilance, pharmacoepidemiology, risk mitigation, medical information and risk evaluation strategies. His duties also consisted of regulatory affairs consulting and outsourcing of operations, Good Clinical Practice, Chemical Manufacturing and Control, and Good Manufacturing practices.
Dr. Tsuetaki had also been the Group President of i3, Inc., Clinical Development Services at the same company. He was the head of a Phase I-III clinical research and also led strategic regulatory offerings. He is also an expert and international leader in medical communications, reimbursement and post-marketing business lines.
He had gained a B.S. degree in the field of nutritional science from the University of California, Davis. He holds a Ph.D in optometry and did his M.S. in the subject physiological optics from the University of Calif. Apart from this he also acquired an MBA degree from Northwestern University’s Kellogg Graduate School of Management.
PAREXEL International Corporation (NASDAQ:PRXL)’s President and Chief Operating Officer, Mark A. Goldberg welcomed Dr. Tsuetaki to the company saying that his range of experiences in various industry segments will help the company manifolds. He said that the competitive market demands accelerated drug development for a company to develop its market presence. In this regards, he said, Dr. Tsuetaki will support the company to provide novel peri-approval and post-approval consulting and services to the industry.
